Table Of Contents
1 Introduction 18
1.1 Overview Of Europe Advanced Wound Care Market 18
1.2 Currency And Pricing 20
1.3 Limitation 20
1.4 Markets Covered 21
2 Market Segmentation 24
2.1 Markets Covered 24
2.2 Geographic Scope 25
2.3 Years Considered For The Study 26
2.4 Currency And Pricing 26
2.5 Research Methodology 27
2.6 Primary Interviews With Key Opinion Leaders 30
2.7 Secondary Sources 31
2.8 Assumptions 31
3 Market Overview 32
3.1 Drivers 34
3.1.1 Rising Ageing And Geriatric Population 34
3.1.2 Technological Advancement 34
3.1.3 Government Support 35
3.1.4 Rising Incidences Of Chronic Wound 36
3.1.5 Increasing Trend 37
3.2 Restraints 37
3.2.1 Low Awareness 37
3.2.2 Slow Growth Rate And Shrinking Market 38
3.2.3 Complex Regulatory Approval Process 38
3.2.4 Competition With Other Moist Dressings 39
3.3 Opportunities 39
3.3.1 Reimbursement 39
3.3.2 Mergers And Acquisitions To Expand Business 40
3.3.3 Unmet Needs 40
3.3.4 Increasing Demand 41
3.4 Challenges 41
3.4.1 Shortage Of Trained Staff 41
3.4.2 The Development Of Substitute Products 41
3.5 Key Market Trends And Upcomming Technologies 42
3.5.1 Smart Dressing Will Push Future Growth 42
3.5.2 Hydrofiber Has Been The Most Significant Recent Innovation 42
3.5.3 Alginate Dressing Is Expected To Grow Robustly In The Upcoming Years 42
3.5.4 Foam Dressing Accounting The Largest Market Segment In The Upcoming Years 42
4 Executive Summary 43
5 Premium Insights 46
6 Europe Advanced Wound Care Market, By Product Type 49
6.1 Overview 50
6.2 Dressing 52
6.2.1 Dressing On The Basis Of Product Type 53
6.2.1.1 Film Dressings 53
6.2.1.2 Foam Dressings 54
6.2.1.3 Hydrogels 54
6.2.1.4 Alginates 55
6.2.1.5 Wound Contact Layer 55
6.2.1.6 Super Absorbent Dressing 56
6.3 Biologics 57
6.3.1 Biologics On The Basis Of Product Type 57
6.3.1.1 Allografts 58
6.3.1.2 Synthetic Skin Grafts 58
6.3.1.3 Xenografts 58
6.3.1.4 Growth Factors 59
6.3.1.4.1 Platelet Derived Growth Factor (Pdgf) 59
6.3.1.4.2 Platelet Rich Plasma (Prp) 59
6.3.1.4.3 Epidermal Growth Factors (Egf) 61
6.3.1.4.4 Basic Fibroblast Growth Factors (Bfgf) 61
6.3.1.4.5 Granulocyte Colony Stimulating Factor (G-Csf) 61
6.3.1.4.6 Talactoferrin Alfa 62
6.3.1.4.7 Thrombin Peptide 62
6.3.1.4.8 Keratinocy Growth Factor (Kgf) 62
6.4 Therapy Devices 63
6.4.1 Therapy Devices On The Basis Of Product Type 63
6.4.1.1 Negative Pressure Wound Therapy (Npwt) 64
6.4.1.1.1 Portable Npwt Devices 64
6.4.1.1.2 Disposable Npwt Devices 65
6.4.1.2 Pressure Relief Devices 65
6.4.1.3 Hyperbaric Oxygen Chambers 65
6.4.1.3.1 Monoplace 65
6.4.1.3.2 Multiplace 66
6.4.1.3.3 Topical 66
6.4.1.4 Wound Debridement Devices 67
6.4.1.4.1 Hydrosurgical 67
6.4.1.4.2 Ultrasound 67
6.4.1.4.3 Mechanical 67
6.4.1.4.4 Others 67
6.4.1.5 Physical Therapies 68
6.4.1.5.1 Laser Therapy 68
6.4.1.5.2 Electrical Stimulation 68
6.4.1.5.3 External Shock Wave Therapies 69
6.4.1.5.4 Saline Mist Therapy 69
7 Europe Advanced Wound Care Market, By Wound Type 70
70
7.1 Introduction 71
7.2 Surgical Wound 73
7.2.1 Class I 73
7.2.2 Class Ii 73
7.2.3 Class Iii 73
7.2.4 Class Iv 73
7.3 Diabetic Ulcers 74
7.4 Pressure Ulcers 75
7.5 Venous Ulcers 76
7.6 Burns 76
8 Europe Advanced Wound Care Market, By End User 77
8.1 Overview 78
8.2 Hospitals 79
8.3 Wound Care Centers 79
8.4 Ambulatory Centers 79
8.5 Home Healthcare 79
8.6 Clinics 80
8.7 Community Healthcare 80
9 Europe Advanced Wound Care Market, By Distribution Channel 81
9.1 Overview 82
9.2 Direct Tenders 82
9.3 Retail 82
10 Europe Advanced Wound Care Market By Geography 83
10.1 Europe 83
10.1.1 Germany 96
10.1.2 France 103
10.1.3 U.K. 110
10.1.4 Italy 117
10.1.5 Spain 124
10.1.6 Russia 131
10.1.7 Netherlands 138
10.1.8 Switzerland 145
10.1.9 Belgium 152
10.1.10 Turkey 159
10.1.11 Rest Of Europe 166
11 Europe Advanced Wound Care Market, Company Share 167
11.1 Company Share Analysis; Europe 167
12 Company Profile 168
12.1 Acelity L.P. Inc. (Subsidary Of Allargan) 168
12.1.1 Company Overview 168
12.1.2 Company Share Analysis 168
12.1.3 Product Portfolio 169
12.1.4 Recent Developments 171
12.2 Smith And Nephew 172
12.2.1 Company Overview 172
12.2.2 Company Share Analysis 172
12.2.3 Revenue Analysis 173
12.2.4 Product Portfolio 173
12.2.5 Recent Developments 174
12.3 Molnlycke Healthcare 175
12.3.1 Company Overview 175
12.3.2 Company Share Analysis 175
12.3.3 Europe Presence 176
12.3.4 Product Portfolio 176
12.3.5 Recent Developments 177
12.4 3M 178
12.4.1 Company Overview 178
12.4.2 Company Share Analysis 178
12.4.3 Revenue Analysis 179
12.4.4 Product Portfolio 179
12.4.5 Recent Developments 181
12.5 Baxter 182
12.5.1 Company Overview 182
12.5.2 Revenue Analysis 182
12.5.3 Product Portfolio 183
12.5.4 Recent Developments 183
12.6 Coloplast 184
12.6.1 Company Overview 184
12.6.2 Revenue Analysis 184
12.6.3 Product Portfolio 185
12.6.4 Recent Developments 185
12.7 Convatec Inc. 186
12.7.1 Company Overview 186
12.7.2 Revenue Analysis 186
12.7.3 Product Portfolio 187
12.7.4 Recent Developments 188
12.8 Derma Sciences Inc (Subsidiary Of Integra Life Sciences) 189
12.8.1 Company Overview 189
12.8.2 Europe Presence 189
12.8.3 Product Portfolio 189
12.8.4 Recent Developments 191
12.9 Ethicon Inc (Subsidiary Of Johnson And Johnson Services, Inc ) 192
12.9.1 Company Overview 192
12.9.2 Europe Presence 192
12.9.3 Product Portfolio 193
12.9.4 Recent Developments 193
12.10 Integra Life Sciences Corporation 194
12.10.1 Company Overview 194
12.10.2 Revenue Analysis 194
12.10.3 Product Portfolio 195
12.10.4 Recent Developments 196
12.11 Paul Hartmann Limited 197
12.11.1 Company Overview 197
12.11.2 Revenue Analysis 197
12.11.3 Product Portfolio 198
12.11.4 Recent Development 198
?
12.12 Organogenesis Inc 199
12.12.1 Company Overview 199
12.12.2 Europe Presence 199
12.12.3 Product Portfolio 200
12.12.4 Recent Developments 200
13 Related Reports 201